Datavault AI Licenses Technology to Wellgistics Health to Tackle PBM-Driven Drug Pricing Inefficiencies
Datavault AI Inc. has granted an exclusive patent license to Wellgistics Health for its PharmacyChain platform, aiming to reduce prescription drug costs by bypassing traditional pharmacy benefit managers.
Datavault AI Inc. (NASDAQ: DVLT) announced an exclusive patent licensing agreement with Wellgistics Health Inc., granting the company sole access within its market segment to Datavault AI’s proprietary technologies. The agreement targets inefficiencies in prescription drug pricing driven by pharmacy benefit managers (PBMs), which contribute to the United States having among the highest drug prices globally.
At the center of the initiative is PharmacyChain, a platform designed to track and manage prescription fulfillment from manufacturer to patient while automating processes traditionally routed through PBMs. By granting exclusivity, Datavault AI creates a stronger commercial incentive for adoption while reinforcing the value of its intellectual property portfolio.
The U.S. prescription drug market is characterized by complex rebate structures controlled by PBMs, which often obscure true drug costs and limit competition. PharmacyChain aims to streamline distribution, reduce reliance on intermediaries, and potentially lower costs for consumers and payers. According to the company, the agreement outlines an exclusive patent license granted to Wellgistics Health, giving the company sole access within its market segment to Datavault AI’s proprietary technologies.
This move positions Datavault AI, a technology company focused on AI-driven data monetization and digital asset infrastructure, at the intersection of healthcare and blockchain-based supply chain management. The partnership with Wellgistics Health leverages Datavault AI’s intellectual property to address a pressing issue in the pharmaceutical industry: the lack of transparency and high costs associated with PBM-driven pricing models.
For investors, this agreement represents a strategic expansion into the healthcare sector, potentially opening new revenue streams for Datavault AI. The latest news and updates relating to DVLT are available in the company’s newsroom at https://ibn.fm/DVLT.
The implications of this announcement extend beyond the companies involved. If successful, PharmacyChain could serve as a model for disrupting PBM dominance, promoting price transparency, and reducing healthcare costs. As regulatory scrutiny of PBMs intensifies, solutions that offer alternative distribution channels may gain traction among policymakers and industry stakeholders.
This development underscores the growing role of AI and blockchain technologies in healthcare supply chain management. By automating processes and providing end-to-end visibility, platforms like PharmacyChain could reshape how prescription drugs are priced and delivered in the United States.